BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President

  In this expanded role, Dr. Turkel will now be responsible global R&D as well as commercial strategy and development.

  November 7, 2017

   · 

  4 min read
• Business

  Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017

  Invitae today announced financial and operating results for the quarter ended September 30, 2017, including continued business momentum, double-digit sequential volume and revenue growth, and a strengthened financial position.

  November 7, 2017

   · 

  17 min read
• Business

  CTI BioPharma Reports Third Quarter 2017 Financial Results

  In July 2017, the first patient was enrolled in PAC203, a Phase II clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy.

  November 7, 2017

   · 

  16 min read
• Business

  Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  Protagonist Therapeutics today reported its financial results for the third quarter and nine months ended September 30, 2017 and provided an update on the company’s recent achievements.

  November 7, 2017

   · 

  14 min read
• Policy

  Ionis Announces Submission of NDA for Inotersen to the FDA

  Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR, to treat patients with TTR amyloidosis, a severe, rare and fatal disease.

  November 7, 2017

   · 

  9 min read
• Business

  Nevro Reports Third Quarter 2017 Financial Results

  Revenue for the three months ended September 30, 2017 was $82.3M versus $60.9M during the same period of the prior year, representing 35% growth as reported.

  November 7, 2017

   · 

  13 min read
• Business

  Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance

  For the fiscal 2018 first quarter, net sales were $155M compared with $161.6M for the first quarter of fiscal 2017.

  November 7, 2017

   · 

  43 min read
• CryoLife Announces Enrollment of First Patients in BioGlue Clinical Trial in China

  The results from the trial will serve as the basis of the Company’s regulatory submission to the CFDA to gain approval to commercialize BioGlue in China. Patients are currently being enrolled at multiple heart centers in China.

  November 7, 2017

   · 

  4 min read
• Biotech Bay

  Impax Announces Successful Completion of Consent Solicitation With Respect to its 2.00% Convertible Senior Notes Due 2022

  Impax Labs announced today that it has received the consents necessary to amend and insert certain provisions in the indenture dated as of June 30, 2015 between the Company and Wilmington Trust, National Association, as trustee, governing its 2.00% Convertible Senior Notes due 2022.

  November 7, 2017

   · 

  5 min read
• TSO3 Reports Record Third Quarter 2017 Results

  Revenue increased to $5.1M, an 11% sequential increase over the $4.6M recorded in the second quarter of 2017 and a 46% increase over the $3.5M recorded in the third quarter of 2016.

  November 7, 2017

   · 

  15 min read